Drug-eluting stents for coronary artery disease: a review
- PMID: 21075668
- DOI: 10.1016/j.medengphy.2010.10.009
Drug-eluting stents for coronary artery disease: a review
Abstract
Over the past decade the introduction of drug-eluting stents (DESs) has revolutionised the treatment of coronary artery disease. However, in recent years concern has arisen over the long-term safety and efficacy of DESs due to the occurrence of late adverse clinical events such as stent thrombosis. With this concern in mind, research and development is currently centred on increasing the long-term safety and efficacy of DESs. The aim of this paper is to provide a thorough review of currently approved and promising investigational DESs. With dozens of companies involved in the development of new and innovative anti-restenotic agents, polymeric coatings and stent platforms, it is intended that this review paper will provide a clear indication of how DESs are currently evolving and prove a valuable reference tool for future research in this area.
Copyright © 2010 IPEM. Published by Elsevier Ltd. All rights reserved.
Similar articles
-
Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.Coron Artery Dis. 2010 Jan;21(1):46-56. doi: 10.1097/MCA.0b013e328333f550. Coron Artery Dis. 2010. PMID: 19952925 Review.
-
Design criteria for the ideal drug-eluting stent.Am J Cardiol. 2007 Oct 22;100(8B):3M-9M. doi: 10.1016/j.amjcard.2007.08.016. Am J Cardiol. 2007. PMID: 17950830 Review.
-
Antiplatelet therapy in the era of drug-eluting stents: current and future perspectives.Expert Rev Cardiovasc Ther. 2007 Sep;5(5):939-53. doi: 10.1586/14779072.5.5.939. Expert Rev Cardiovasc Ther. 2007. PMID: 17867923 Review.
-
A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) - study design and rationale.J Cardiovasc Med (Hagerstown). 2009 Feb;10(2):192-9. doi: 10.2459/JCM.0b013e32831f9176. J Cardiovasc Med (Hagerstown). 2009. PMID: 19377384 Clinical Trial.
-
A critical appraisal of the safety and efficacy of drug-eluting stents.Clin Pharmacol Ther. 2009 May;85(5):474-80. doi: 10.1038/clpt.2009.8. Epub 2009 Mar 11. Clin Pharmacol Ther. 2009. PMID: 19279567 Review.
Cited by
-
The Effect of Fluid Shear Stress on the In Vitro Release Kinetics of Sirolimus from PLGA Films.Polymers (Basel). 2017 Nov 15;9(11):618. doi: 10.3390/polym9110618. Polymers (Basel). 2017. PMID: 30965925 Free PMC article.
-
"Rescue administration" of intracoronary thrombolytic therapy for drug-eluting stent thrombosis.Herz. 2014 Aug;39(5):647-50. doi: 10.1007/s00059-013-3876-1. Epub 2013 Jul 24. Herz. 2014. PMID: 23949549
-
Magnetically targeted delivery of therapeutic agents to injured blood vessels for prevention of in-stent restenosis.Methodist Debakey Cardiovasc J. 2012 Jan;8(1):23-7. doi: 10.14797/mdcj-8-1-23. Methodist Debakey Cardiovasc J. 2012. PMID: 22891107 Free PMC article. Review.
-
Fabrication of a multilayer bioabsorbable composite vascular stent utilizing oxidized starch-Fe3O4 nanoparticles and polycaprolactone nanofibers.Sci Rep. 2025 Mar 3;15(1):7454. doi: 10.1038/s41598-025-86111-x. Sci Rep. 2025. PMID: 40032856 Free PMC article.
-
Evaluation of coronary stents: A review of types, materials, processing techniques, design, and problems.Heliyon. 2023 Feb 9;9(2):e13575. doi: 10.1016/j.heliyon.2023.e13575. eCollection 2023 Feb. Heliyon. 2023. PMID: 36846695 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous